Insider Selling: Urogen Pharma (NASDAQ:URGN) General Counsel Sells $147,261.51 in Stock

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Urogen Pharma Stock Performance

NASDAQ:URGN opened at $20.10 on Friday. The stock has a 50-day simple moving average of $21.57 and a two-hundred day simple moving average of $20.73. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00. The firm has a market capitalization of $940.88 million, a PE ratio of -5.81 and a beta of 1.32.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the last quarter. State of Wyoming purchased a new position in shares of Urogen Pharma during the third quarter valued at about $66,000. Russell Investments Group Ltd. grew its position in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Urogen Pharma in the third quarter worth about $76,000. Institutional investors own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

URGN has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Friday, January 23rd. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.